Azbec 100 Inhaler

Azbec 100 Inhaler (Beclomethasone Dipropionate 100mcg) — Clinical Overview

About Azbec 100 Inhaler

Azbec 100 Inhaler is beclomethasone dipropionate 100 micrograms per actuation pressurised metered dose inhaler (pMDI), manufactured by Eskayef Bangladesh Ltd. Beclomethasone dipropionate (BDP) is a halogenated glucocorticoid and one of the oldest and most extensively studied inhaled corticosteroids, having been in clinical use since the 1970s. It remains a WHO Essential Medicine and a core component of GINA (Global Initiative for Asthma) guideline-recommended asthma management regimens. Azbec 100 Inhaler is indicated for the prophylactic management of asthma — it must be used regularly for sustained benefit and is not intended for acute bronchospasm relief, for which a short-acting beta-2 agonist (such as salbutamol) is required.

Eskayef Bangladesh Ltd. (formerly Smith Kline & French) is one of Bangladesh's longest-established pharmaceutical manufacturers. Azbec represents Eskayef's flagship inhaled corticosteroid product, providing affordable access to preventive asthma therapy for Bangladeshi patients. Beclomethasone 100mcg per actuation is the standard low-to-medium dose ICS formulation suitable for step 2 and step 3 asthma management per GINA guidelines.

Mechanism of Action — How Beclomethasone Controls Asthma

Asthma is fundamentally a chronic inflammatory disease of the airways. Beclomethasone dipropionate exerts its therapeutic effect by binding to intracellular glucocorticoid receptors in airway epithelial cells, mast cells, eosinophils, and macrophages. This receptor binding triggers a cascade of anti-inflammatory effects: suppression of cytokine production (interleukins IL-4, IL-5, IL-13 that drive eosinophilic inflammation); inhibition of arachidonic acid release and prostaglandin/leukotriene synthesis; reduction in mast cell numbers and mediator release; decreased mucus secretion and airway oedema; and restoration of beta-2 adrenergic receptor sensitivity (which can be reduced in acute asthma). These combined effects reduce airway hyperresponsiveness, decrease bronchial mucosal oedema, and reduce the frequency and severity of asthma exacerbations. Regular use for 2–4 weeks produces measurable improvement in peak expiratory flow (PEF), FEV1, and symptom control. Maximum benefit is typically seen after 4–8 weeks of regular use.

Dosing and GINA Step Therapy

Azbec 100 Inhaler dosing follows GINA step therapy guidelines: GINA Step 2 (mild persistent asthma) — low-dose ICS: BDP 100–200 mcg/day = 1–2 puffs of Azbec 100 once or twice daily; GINA Step 3 (moderate persistent asthma) — low-to-medium dose ICS + LABA: BDP 200–400 mcg/day = 2–4 puffs of Azbec 100 daily in divided doses, usually combined with a long-acting beta-2 agonist (salmeterol, formoterol); GINA Step 4 (severe persistent asthma) — medium-to-high dose ICS + LABA: BDP 400–800 mcg/day = 4–8 puffs of Azbec 100 daily. Adult standard starting dose for most newly diagnosed patients: 2 puffs (200 mcg) twice daily (morning and evening) — total 400 mcg/day. Children (5–12 years): 1–2 puffs (100–200 mcg) twice daily. After achieving stable asthma control for 3 months, the dose may be stepped down to the minimum effective dose maintaining control.

Inhaler Technique — Critical for Effective Delivery

Up to 80% of patients use MDI inhalers incorrectly, significantly reducing drug delivery to the lungs. Correct technique for Azbec 100 pMDI: (1) Remove cap and shake the inhaler well for 5 seconds. (2) Breathe out slowly and fully. (3) Place the mouthpiece between the lips, forming a tight seal — do not bite the mouthpiece. (4) Begin to breathe in slowly and deeply through the mouth. (5) Immediately after starting to breathe in, press down firmly on the canister once to release one actuation. (6) Continue breathing in slowly for 3–5 seconds until the lungs are full. (7) Remove the inhaler and hold the breath for 10 seconds (or as long as comfortably possible). (8) Breathe out slowly. (9) Wait 30–60 seconds before the second puff if two puffs are prescribed. (10) After each use, rinse the mouth with water and spit out — this prevents oropharyngeal candidiasis (oral thrush), the most common local side effect of inhaled corticosteroids. Use of a spacer device is strongly recommended — it significantly improves drug delivery to the lungs, reduces oropharyngeal deposition, and is essential for children and for patients who find coordination of inhalation and actuation difficult.

Frequently Asked Questions (FAQ)

Q1: Can Azbec 100 Inhaler be used during an acute asthma attack?
No — Azbec 100 Inhaler is a preventer inhaler (inhaled corticosteroid), not a reliever. It works by reducing airway inflammation over days to weeks and has no bronchodilator effect. During an acute asthma attack, the appropriate treatment is a short-acting beta-2 agonist reliever inhaler such as salbutamol (Ventolin, Asthalin) — 2–4 puffs every 20 minutes for up to 1 hour for a moderate attack. All asthma patients using a preventer inhaler like Azbec 100 should also be prescribed and carry a salbutamol reliever inhaler for acute symptom relief. Seek emergency medical attention if the reliever inhaler does not provide adequate relief within 20 minutes.

Q2: How long before Azbec 100 Inhaler starts working?
Beclomethasone dipropionate (Azbec 100) reduces airway inflammation gradually over time — it does not provide immediate symptom relief. Measurable improvements in lung function (PEF, FEV1) typically begin within 1–2 weeks of starting regular use. Significant improvement in symptom control, reduced frequency of reliever inhaler use, and fewer nocturnal symptoms typically occurs within 4–6 weeks. Maximum benefit is often not achieved until 8–12 weeks of consistent daily use. This delayed onset is normal and expected — it is not a sign that the inhaler is not working. Patients should continue using Azbec 100 regularly every day even when they feel well, as the inhaler prevents symptoms from occurring rather than relieving them once they develop.

Q3: Will long-term use of Azbec 100 cause steroid side effects like weight gain or bone loss?
At the low-to-medium doses used in asthma management (100–400 mcg/day of beclomethasone), systemic side effects are rare because inhaled corticosteroids act locally in the airways with minimal systemic absorption. The inhaled route delivers the drug directly to the target tissue (bronchial mucosa) with only a small fraction reaching the systemic circulation. At therapeutic doses, clinically significant weight gain, adrenal suppression, osteoporosis, or other systemic corticosteroid effects are very unlikely. Local side effects — oropharyngeal candidiasis (oral thrush) and hoarseness — occur in 5–10% of users and are effectively prevented by rinsing the mouth after each use. The benefits of well-controlled asthma (preventing exacerbations, hospitalisation, and systemic oral steroid use) far outweigh the small local side effect risk.

Q4: My child was prescribed Azbec 100 Inhaler — will it affect their growth?
At recommended paediatric doses, inhaled beclomethasone has minimal effect on growth. A small reduction in growth velocity (approximately 0.5 cm per year) has been documented in some studies with higher-dose ICS, particularly in the first year of treatment. However, uncontrolled asthma itself impairs growth more significantly than low-dose ICS therapy — children with poorly controlled asthma frequently miss school, sleep poorly due to nocturnal symptoms, and may require oral steroids during exacerbations (which have a much greater impact on growth). The paediatric respiratory specialist or physician prescribing Azbec 100 will use the minimum effective dose and reassess growth regularly. The benefits of asthma control in children outweigh the minimal growth risk at recommended doses.

Medical Disclaimer: Azbec 100 Inhaler is a prescription medication. Asthma management should be supervised by a physician. Never stop or change your inhaler regimen without medical advice. Always carry a short-acting reliever inhaler for acute symptoms. Correct inhaler technique is essential — ask your pharmacist or physician for a demonstration.